Peptonic announces outcome in the rights issue and the directed issue | Placera
Summary
Upon full exercise of all warrants of series TO5, the Company may be provided with an additional capital injection of up to approximately SEK 27.4 million.All holders of interim shares were offered to participate in the Directed Issue with deviation from the existing shareholders preferential rights. The capital raised from the share issue provides Peptonic with the resources to continue growing, particularly in the USA and Europe, and to drive sales growth both through partnerships with international partners and our own operations. The information was submitted for publication, through the agency of the contact person, on June 14th, 2024 10:15 CEST.Peptonic medical AB (publ) is an innovative Swedish biomedical company engaged in the development and sales of clinically proven self-care treatments and self-diagnostic rapid tests in intimate womens health. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information.